Presentation Details

Suven Life Sciences will present two scientific presentations:

Presentation P033: Masupirdine (SUVN-502)

  • Pure 5-HT6 receptor antagonist
  • Phase-3 clinical study targeting agitation in patients with dementia of Alzheimer's type
  • Presentation will cover baseline demographic and clinical characteristics of patients enrolled in the global Phase-3 study
  • Enrollment in the global Phase-3 Masupirdine AAD study has been completed
  • Baseline characteristics are consistent with published studies and represent quality AD population with Agitation
  • No major safety concerns identified to date
  • Topline results expected in Q2 2027

Presentation P066: Tenaclidine (SUVN-I6107)

  • Pure M1 positive allosteric modulator
  • Phase-1 first-in-human evaluation
  • Presentation will cover outcomes from single ascending dose (SAD) and multiple ascending dose (MAD) studies in healthy subjects
  • Includes safety, tolerability and pharmacokinetics data
  • Effects of food, age and gender on pharmacokinetic profile will be presented
  • Phase-1 study is completed
  • Long term general toxicity and developmental toxicity studies in nonclinical models are in progress

Management Commentary

Mr. Venkat Jasti, Chairman and Managing Director, stated: "Completion of enrolment in the global Phase-3 Masupirdine AAD study marks an important milestone in the clinical development. Very glad to report the baseline characteristics are consistent with the published studies, representative of quality AD population with Agitation and no major safety concerns have been identified to date. We look forward to the topline results as scheduled in Q2-2027. We are very encouraged by the clinical findings for Tenaclidine, to move forward to the patient studies. The progress reflects our continued efforts to advance innovative therapeutic approaches addressing significant unmet needs in CNS disorders."

Company Business Overview

Suven Life Sciences is a clinical-stage biopharmaceutical company focused on discovering and developing innovative medicines for CNS disorders. The company has a portfolio of 5 clinical stage assets:

1. Masupirdine (SUVN-502): For treatment of agitation in patients with dementia of Alzheimer's type (Global Phase-3 study ongoing, enrollment completed)

2. Samelisant (SUVN-G3031): For excessive daytime sleepiness (EDS) in narcolepsy (Phase-2 study for EDS completed; pivotal Phase-3 AWAKE study for EDS initiated; Phase-2 study for Cataplexy in planning)

3. Ropanicant (SUVN-911): For major depressive disorders (MDD) (Open-label Phase-2a study completed; Double blind randomized Placebo controlled Phase-2b study completed; Phase-3 study in planning)

4. Usmarapride (SUVN-D4010): For cognitive disorders (Phase-2 study in planning)

5. Tenaclidine (SUVN-I6107): For cognitive disorders (Phase-1 study completed)

Additionally, the company has seven projects in research pipeline across multiple indications. Suven owns all intellectual property rights for its assets in all major world markets.

Risk Disclosure

The news release contains forward-looking statements that involve several risks and uncertainties. Important factors which could cause results to differ materially include: outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances, and continued success in growth of sales that may make products/services offerings less competitive.